ClinicalTrials.gg
CompletedNCT05086822Updated Oct 21, 2021

A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors

A Phase 1 interventional study of Irinotecan liposome in Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-21.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years after the study started (first participant enrolled Sep 2014, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is an open label, dose-escalation and expansion, single centre, phase Ia study . In this study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride liposome injection were studied in patients with advanced solid tumors, to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan hydrochloride liposome.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed solid tumors documented as advanced or disease;
  2. Subjects must be considered to standard therapies, have been intolerant to standard therapies, or have refused standard therapy;
  3. : 0-1;
  4. Adequate organ and bone marrow function;
  5. sign an .

Exclusion criteria

Exclusion Criteria:

  1. Patients with brain malignant tumor, lymphoma or other malignant hematologic diseases;
  2. Active ;
  3. GI disorders;
  4. Significant cardiovascular disease;
  5. Active infection or uncontrolled fever;
  6. Pregnant or breast feeding patients;
  7. Allergic to a drug ingredient or component;
  8. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Treatment group : Irinotecan liposome

    Drug: Irinotecan liposome

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event (AE)

    Assessed by CTCAE 4.03

    Time frame: Assessed from study inclusion to 30 days after last dose

  2. Dose Limiting Toxicities (DLT)

    Dose limiting toxicities for patients in the treatment

    Time frame: DLTs will be evaluated during 21-day period following the first dose of study treatment

  3. Maximal tolerated dose (MTD)

    Maximum tolerated dose for patients in the treatment

    Time frame: after the last patient in each cohort up to 12 months

Secondary outcomes

  1. Objective Response Rate

    Objective response rate was based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: maximum time on study 12 months

  2. Progression Free Survival

    Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurs first.

    Time frame: The maximum time in follow up was 12 months

  3. Time to reach maximum plasma concentration (Tmax)

    Tmax of total irinotecan, free irinotecan and SN-38

    Time frame: up to 120 hours after the first dose

  4. Maximum observed plasma concentration (Cmax)

    Cmax of total irinotecan, free irinotecan and SN-38

    Time frame: up to 120 hours after the first dose

  5. Area under the plasma concentration versus time curve from time zero to time of last observed concentration (AUC0-t)

    AUC0-t of total irinotecan, free irinotecan and SN-38

    Time frame: up to 120 hours after the first dose

  6. Area under the plasma concentration versus time curve from time zero to infinity (AUC0-inf)

    AUC0-inf of total irinotecan, free irinotecan and SN-38

    Time frame: up to 120 hours after the first dose

  7. Elimination half-life (T1/2)

    T1/2 of total irinotecan, free irinotecan and SN-38

    Time frame: up to 120 hours after the first dose

  8. Clearance of drug from plasma (CL)

    CL of total irinotecan

    Time frame: up to 120 hours after the first dose

  9. Volume of distribution (Vss)

    Vss of total irinotecan

    Time frame: up to 120 hours after the first dose

07

Study locations

1 site
  • Fudan University Cancer Hospital
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Aug 2017, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2021
First posted
Oct 21, 2021
StartActual
Sep 9, 2014
Primary completionActual
Aug 28, 2017
CompletionActual
Aug 28, 2017
Last update
Oct 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05086822
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Sep 9, 2014
Primary completion
Aug 28, 2017
Completion
Aug 28, 2017
Last update
Oct 21, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion